Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Trial crawled date : 2022 - 02 - 28 save search
Novavax Announces Extended Durability of Protection Against Infection and Disease in United Kingdom COVID-19 Vaccine Phase 3 Clinical Trial
Published: 2022-02-28 (Crawled : 23:00) - biospace.com/
NVAX | $4.13 -3.51% -3.63% 5.3M
|
Health Technology
|
| O: -0.81%
H: 3.12%
C: 2.96%
covid-19 trial covid disease vaccine infection phase 3 infections
Shunt Reactor Market in APAC 2022-2026 | Increasing industrialization of the developing nations to boost growth | Technavio
Published: 2022-02-28 (Crawled : 17:00) - prnewswire.com
ABLZF | $46.196 -32.74% 8.6K
|
Producer Manufacturing
|
| O: 3.88%
H: 2.51%
C: -4.47%
ALSMY | $1.5 -1.78% 570K
|
Manufacturing
|
| O: -5.41%
H: 3.63%
C: 0.82%
ABB | $37.13 -0.03% 6.4M
|
Producer Manufacturing
|
| O: 0.82%
H: 0.0%
C: 0.0%
react trial growth
Pliant Therapeutics Announces Positive Data from Expanded Phase 1b BAL Trial of PLN-74809 Demonstrated Suppression of TGF-β Signaling in Healthy Volunteers
Published: 2022-02-28 (Crawled : 15:30) - biospace.com/
PLRX | $13.55 -4.24% -4.43% 270K
|
Health Technology
|
| O: -0.41%
H: 0.0%
C: 0.0%
pln-7480 health phase 1b trial therapeutics phase 1 positive phase 2b
BriaCell Adds Two Clinical Trial Sites to Accelerate Patient Enrollment
Published: 2022-02-28 (Crawled : 15:30) - biospace.com/
BCTX | $2.37 -4.05% -4.22% 36K
|
Professional, Scientific, and T...
|
| O: -1.56%
H: 4.22%
C: 0.66%
trial cel enroll
Green Lights and Setbacks: Clinical Trial Updates for Feb. 21-25
Published: 2022-02-28 (Crawled : 15:00) - biospace.com/
OTIC | $0.077
|
Health Technology
|
| O: -1.51%
H: 4.59%
C: 3.06%
trial set
Pause of GSK's RSV Vaccine Trials in Pregnant Women Deepens
Published: 2022-02-28 (Crawled : 15:00) - biospace.com/
JNJ | $147.59 0.05% 0.0% 8.5M
|
Health Technology
|
| O: 1.79%
H: 0.0%
C: 0.0%
SNY | $46.22 0.63% 0.63% 1.7M
|
Health Technology
|
| O: -0.49%
H: 0.0%
C: 0.0%
als trials trial women vaccine
Zynerba Pharmaceuticals Announces Completion of Enrollment in Phase 2 Trial of Zygel™ in 22q11.2 Deletion SyndromeTopline data from Phase 2 INSPIRE trial expected mid-year 2022
Published: 2022-02-28 (Crawled : 14:30) - biospace.com/
ZYNE | $1.3 3.08% 860K
|
Health Technology
|
| O: -4.76%
H: 0.0%
C: 0.0%
phase 2 als trial topline enroll zygel
Seelos Therapeutics Announces Dosing of the First Participants in a Registrational Phase II/III Trial of SLS-005 in Amyotrophic Lateral Sclerosis on the HEALEY ALS Platform
Published: 2022-02-28 (Crawled : 14:00) - biospace.com/
SEEL | $0.4263 -7.75% -8.4% 290K
|
Health Technology
|
| O: -0.94%
H: 5.71%
C: 0.95%
sls-005 als trial therapeutics sclerosis platform
Zynerba Pharmaceuticals Announces Completion of Enrollment in Phase 2 Trial of Zygel™ in 22q11.2 Deletion Syndrome
Published: 2022-02-28 (Crawled : 13:30) - zynerba.com
ZYNE | $1.3 3.08% 860K
|
Health Technology
|
| O: -4.76%
H: 0.0%
C: 0.0%
phase 2 als trial syndros enroll zygel
Lyra Therapeutics Announces First Patient Dosed in Pivotal ENLIGHTEN I Clinical Trial of LYR-210 in Chronic Rhinosinusitis Patients
Published: 2022-02-28 (Crawled : 13:30) - biospace.com/
LYRA | $5.26 -0.38% -0.38% 240K
|
Health Technology
|
| O: -1.94%
H: 5.94%
C: -3.56%
lyr-210 ces trial therapeutics
Humacyte Announces Publication of Positive Long-Term Follow-Up Data from Phase 2 Trial of HAV™ for Hemodialysis
Published: 2022-02-28 (Crawled : 13:00) - biospace.com/
HUMA | $2.88 0.0% 750K
|
Manufacturing
|
| O: -1.05%
H: 0.0%
C: 0.0%
hemodialysis phase 2 trial positive
Durable and Deepening Clinical Responses Observed in Post-Treatment Period of Evelo Bioscience’s Phase 2 Clinical Trial of Oral EDP1815 in Psoriasis
Published: 2022-02-28 (Crawled : 12:00) - biospace.com/
EVLO | $0.3165 -87.39% 710K
|
Health Technology
|
| O: 0.0%
H: 2.64%
C: -8.36%
edp1815 treatment phase 2 trial response psoriasis pons bioscience
Celyad Oncology Announces Voluntary Pause of CYAD-101-002 Phase 1b Trial
Published: 2022-02-28 (Crawled : 08:00) - globenewswire.com
CYAD | $0.47 -12.49% 49K
|
Health Technology
|
| O: -10.87%
H: 0.7%
C: -6.97%
cyad-101 phase 1b trial cel phase 1 phase 2b
Moody’s Investors Service upgrades senior unsecured rating of CNH Industrial N.V. from Baa3 to Baa2
Published: 2022-02-28 (Crawled : 07:00) - globenewswire.com
CNHI | $12.7 0.55% 0.0% 7.5M
|
Producer Manufacturing
|
| O: -3.49%
H: 0.0%
C: 0.0%
trial
Bavarian Nordic Reports Additional Positive Phase 2 Results for its COVID-19 Vaccine Candidate Ahead of Phase 3 Trial
Published: 2022-02-28 (Crawled : 07:00) - globenewswire.com
JNJ | $147.59 0.05% 0.0% 8.5M
|
Health Technology
|
| O: 1.79%
H: 0.0%
C: 0.0%
covid-19 phase 2 trial covid report positive phase 2 results results vaccine phase 3
Gainers vs Losers
| 49% | 51% |
Top 10 Gainers
KAVL | $6.275 135.02% 57.45% 44M
|
Wholesale Trade
PXMD | $0.7375 79.09% 44.16% 4.5M
|
Health Technology
DYNT | $0.371 -5.12% 43.09% 3.3M
|
Health Technology
LGVN P 3 d | $2.94 73.96% 42.52% 57M
|
HUBC | $1.94 49.23% 32.99% 73M
|
n/a
SPCB | $0.4044 46.52% 31.75% 130M
|
Electronic Technology
ONVO | $1.34 32.66% 24.62% 54M
|
Health Technology
OMQS | $0.6869 32.1% 24.3% 3.6M
|
Professional, Scientific, and T...
SNPO | $10.555 29.67% 22.88% 4M
|
AMBI | $3.72 -26.77% 21.77% 9.8K
|
n/a
Your saved searches
Save your searches and get alerts when important news are released.